Auvelity approval europe poland dextromethorphan bupropion?

Has Auvelity been approved in Europe, including Poland?

Auvelity (dextromethorphan + bupropion) is an approved medicine in the European Union for major depressive disorder (MDD). Poland is part of the EU medicines market, so regulatory approval for Auvelity carries over through EU marketing authorization into Poland.

What does “Auvelity approval” mean in practice for Poland?

An EU marketing authorization means:
- The medicine can be marketed in EU member states such as Poland.
- Polish availability depends on national steps after authorization (pricing/reimbursement decisions and local launch timing), which can affect when patients actually get access.

Who controls the EU approval, and what regulator is involved for Poland?

EU approvals are granted by the European Commission based on a scientific assessment from EU regulators (not through a separate “Poland-only” approval process). Poland then handles local commercialization requirements after that authorization.

What are the key ingredients and what are they used for?

Auvelity combines dextromethorphan and bupropion and is used to treat major depressive disorder (MDD) in adults, under the approved EU indication.

Where to check the most current Poland/EU status

For the latest patent and exclusivity research related to dextromethorphan/bupropion (and product-specific status details often tied to market events), DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/

Sources

• 1